NASDAQ: ERNAErnexa Therapeutics Inc Stock
$2.25-0.12 (-5.06%)
Updated Jun 13, 2025
ERNA Price
$2.25
Fair Value Price
$0.08
Market Cap
$9.35M
52 Week Low
$2.08
52 Week High
$39.38
P/E
-0.07x
P/B
-1.57x
P/S
17.75x
PEG
N/A
Dividend Yield
N/A
Revenue
$535.00k
Earnings
-$46.09M
Gross Margin
93.5%
Operating Margin
-7,495.14%
Profit Margin
-8,618.7%
Debt to Equity
-1.85
Operating Cash Flow
-$14M
Beta
1.44
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ERNA Overview
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ERNA's potential to beat the market
- ERNA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ERNA
RankedUnranked of 464
RankedUnranked of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important ERNA news, forecast changes, insider trades & much more!
ERNA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ERNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ERNA ($2.25) is overvalued by 2,742.33% relative to our estimate of its Fair Value price of $0.08 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ERNA ($2.25) is not significantly undervalued (2,742.33%) relative to our estimate of its Fair Value price of $0.08 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ERNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ERNA due diligence checks available for Premium users.
Valuation
ERNA fair value
Fair Value of ERNA stock based on Discounted Cash Flow (DCF)
Price
$2.25
Fair Value
$0.08
Overvalued by
2,742.33%
ERNA ($2.25) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ERNA ($2.25) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ERNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ERNA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.07x
Industry
-108.97x
Market
31.36x
ERNA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.57x
Industry
4.66x
ERNA's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.2M
Profit Margin
0%
ERNA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ERNA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$5.1M
Liabilities
$11.0M
Debt to equity
-1.85
ERNA's short-term liabilities ($10.44M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ERNA's short-term assets ($2.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ERNA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ERNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.1M
Investing
$0.0
Financing
$2.3M
ERNA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ERNA vs Biotech Stocks
Ernexa Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.